Journal
TRANSPLANT INTERNATIONAL
Volume 18, Issue 3, Pages 366-368Publisher
WILEY
DOI: 10.1111/j.1432-2277.2004.00070.x
Keywords
amyloidosis; juvenile rheumatoid arthritis; kidney transplantation; rapamycin
Categories
Ask authors/readers for more resources
Juvenile rheumatoid arthritis (JRA) is an immune-mediated disease characterized by articular inflammation and subsequent tissue damage that may result in severe disability. Several combinations of drugs, including immunosuppressive agents have been used to control disease progression. Although there is no information available on rapamycin efficacy in IRA, it has demonstrated a potential to inhibit inflammatory processes observed in adult rheumatoid arthritis (RA). We present a 21 years old renal transplant recipient with IRA, primarily treated with tacrolimus and steroids, who achieved a long-term disease remission after introduction of rapamycin. As long as pathogenesis of IRA and RA is similar, we conclude that rapamycin could be promising immunosuppressant for patients after renal transplantation suffering from both IRA and RA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available